Keros Q1 net income $148.5M on Takeda license; cash $720.5M; KER-065 Phase 2 plan Q1 2026

Keros Therapeutics, Inc.

2025-Q1 EPS reported $3.62 revenue$211,192,000

Net income of $148.5M vs net loss of $43.1M YoY; revenue driven by Takeda license agreement.
Research and development expenses $48.7M, up from $38.3M YoY, due to pipeline advancement.
Cash and cash equivalents $720.5M expected to fund operations into 2029.
Phase 1 KER-065 topline met objectives; plan to start Phase 2 in Q1 2026 after regulatory engagement.
Phase 2 TROPOS trial of cibotercept (KER-012) in PAH data expected Q2 2025; Board reviewing strategic alternatives.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.